High uric acid: causes, gout and what you can influence yourself
High uric acid usually causes no symptoms, and only some people with a high value ever develop gout. Here you will find why kidneys and genes often shape the value more than your plate, when a joint needs to be seen by a doctor and what guidelines and studies actually offer on lowering it.
Many people know this pattern. Your lab report lists uric acid, with an asterisk next to it. You have no pain, no swollen joint, nothing.
And still, it nags at you. Are you no longer allowed a beer, a steak? Is the apple juice in the morning suddenly a problem?
Or the other way round: you woke up at night because even the duvet on your big toe hurt. And your uric acid was normal.
Both situations become easier to understand once you keep three things apart: the lab value, the crystals and the disease called gout.
When a joint or your flank cannot wait
- A suddenly hot, red, swollen joint with fever, chills or feeling clearly unwell must be seen by a doctor the same day. A septic joint infection has to be ruled out. Extra caution applies after an injury, a joint puncture or surgery and if your immune defense is weakened. The German general practice guideline lists these points among its red flags.
- The first gout attack should always be assessed by a doctor, even if the pain eases after a few days.
- Colicky flank pain, for example from a kidney stone, should be assessed by a doctor promptly. If fever or clearly less urine is added: seek medical help immediately, and if in doubt call the emergency number 112 (the European and German emergency number).
- Skin rash, fever or blisters on the skin or mucous membranes after starting urate-lowering treatment: report this to a doctor right away. The American College of Rheumatology guideline explicitly names severe hypersensitivity reactions to allopurinol, which is why any such reaction belongs in medical hands immediately.
And one sentence that stands above this entire article: Prescribed medications are not stopped, reduced or replaced on your own because of a uric acid value. This applies to allopurinol, febuxostat and colchicine just as much as to water tablets (diuretics), low-dose aspirin, beta blockers and other blood pressure medications. These drugs are prescribed for good reasons. Whether a drug that raises uric acid can be replaced is decided by the prescribing doctor.
Uric acid is not an enemy. It is a messenger that can tell you something about your kidneys, insulin and habits. A gout attack, on the other hand, is not a lab value but an inflammation that needs medical treatment.
What to expect here
- Why no laboratory can give you one normal value for everyone
- How often a high value actually turns into gout
- Kidneys, gut, genes and insulin as the key dials
- Which medications raise the value and why stopping them is not the answer
- Fructose, beer, purines, weight and fasting with their level of evidence
- Blood pressure, kidneys, heart: cause or bystander?
- The gout attack and what the guidelines say
- What you can influence yourself, sorted by evidence
Supported by RCTs, meta-analyses and guidelines
Uric acid as a cause of gout and kidney stones, the treatment of a gout attack, no kidney benefit of allopurinol without gout in large Western trials.
Observed in humans, cause unclear
Associations with drinks, alcohol, coffee, dairy, blood pressure and the heart: patterns, not automatically cause and effect.
Mechanistically plausible, human studies thin
The antioxidant idea, the evolution of uricase, ketone bodies and crystal inflammation: laboratory findings, not clinically tested.
Clinical tradition and my practice
Home remedies such as apple cider vinegar, baking soda or teas have not been studied for uric acid. Where I describe how I proceed in consultations, that is an approach and not a study result.
What uric acid is and why your body does not simply break it down
Your body breaks down and rebuilds cells every day. Every cell contains genetic material, and that genetic material contains building blocks called purines. Purines also come in with food, especially with meat, organ meats and seafood.
When purines are broken down, a small molecule sits at the end of the chain: uric acid. The enzyme that handles the step just before it is called xanthine oxidase. Incidentally, this is exactly where allopurinol and febuxostat act later on.
In most mammals, the process continues. An enzyme called uricase breaks uric acid down into a highly soluble substance that leaves easily with the urine. In humans, this station is missing.
A team around Vitart searched a Croatian population sample genome-wide for genes that regulate uric acid levels, confirmed the findings in further samples and tested transport in a laboratory experiment using frog egg cells.
In the introduction to their paper, the authors summarize the state of knowledge: humans and great apes have lost liver uricase activity and, at 200 to 500 µmol/l, lie far above other mammals at 3 to 120 µmol/l. About 70 percent of daily uric acid leaves the body via the kidneys. The study itself identified SLC2A9, previously known as a fructose transporter, as a new urate transporter.
What this means for you: your body cannot break uric acid down any further. It depends on getting rid of it, and the kidneys are mainly responsible for that.
Vitart V, Rudan I, Hayward C et al. Nat Genet. 2008;40(4):437-42. PMID: 18327257 [Genome-wide association study with laboratory component]Lab Why evolution arranged things this way remains open. A laboratory study around Kratzer reconstructed the uricase enzymes of extinct mammalian ancestors: their activity declined step by step until the gene fell silent in the great apes. The idea that this loss helped convert fructose into fat more quickly is a hypothesis from cell experiments and not evidence in humans.
Waste product or protective substance? Both are discussed
Uric acid has a bad reputation. Yet as early as 1981, Ames and colleagues showed in laboratory experiments with red blood cells that urate can scavenge oxygen radicals, in these experiments roughly as effectively as vitamin C. This gave rise to the hypothesis that uric acid is one of the most important antioxidants in the blood, a hypothesis from the test tube.
A working group around Nakayama goes one step further in a review and writes that the notion "the lower, the better" is not correct. Values that are too high and values that are too low can both cause problems.
The solubility limit: when dissolved suddenly turns solid
As long as uric acid floats dissolved in the blood, you feel nothing. It becomes a problem when it precipitates as a sodium salt, monosodium urate. Under the microscope, these crystals look like tiny needles.
In its diagnostics chapter, the German S3 guideline on gout gives a solubility product of approx. 6.8 to 7 mg/dl, and in its therapy chapter, for body conditions of pH 7.4 and 37 °C, up to approx. 6.5 mg/dl. With cold, poor circulation and in tissue already damaged by osteoarthritis, the limit is lower. That is why it is better to speak of a zone around 6.8 mg/dl than of a sharp cut-off.
Think of sugar in tea. You can stir a lot of sugar into hot tea, and it disappears. If you let the tea go cold, some of it settles at the bottom, and it does so first where it is coldest.
Your big toe is one of the cooler places in your body, far from your warm torso, and its base joint may already be a little worn. That can explain why gout so often starts there.
Around 70 percent of uric acid leaves the body via the kidneys, the rest mainly via the gut. How fructose is processed in the liver and why uric acid can also be produced in the process is explained in detail in Sugar and fructose: the liver is where it happens. Here, the focus is on what happens to uric acid afterwards.
Uric acid is not simply rubbish your body forgot to clear away. It is a substance humans have kept over the course of evolution, with possible functions and with a physical risk.
So the key question is not whether uric acid is there. It is how much of it stays dissolved and where it crystallizes.
And now you know why one and the same substance can remain invisible in the blood and trigger severe pain in a joint.
Uric acid level: why there is no single normal value for everyone
Put two reports from two laboratories side by side. It is quite possible that uric acid comes with two different reference ranges, one in green, one with an asterisk.
That is not a mistake. The German general practice guideline on acute gout states that the reference ranges for serum uric acid given by individual laboratories differ considerably. That is why you deliberately will not find a table of normal values here.
Two different questions: statistics and physics
A reference range describes which values are common in a comparison group. It depends on that comparison group and on the measurement method, and it tells you what is usual. The solubility limit says something else: the point at which uric acid can crystallize under body conditions. A value can therefore be statistically unremarkable and still lie in the zone where crystals can form. The American College of Rheumatology guideline uses the same order of magnitude for asymptomatic hyperuricemia: uric acid above 6.8 mg/dl without previous gout attacks and without gout nodules under the skin.
A word on units: some laboratories report mg/dl, others µmol/l. The NICE guideline equates 6 mg/dl with 360 µmol/l.
The reference range is statistics, solubility is physics. The asterisk on your report answers the question of whether your value is rare. It does not answer whether it means a risk for you.
That second question belongs in a conversation with a practice that knows your kidney values, your medications, your joints and your history. No treatment can be derived from a single value.
Timing changes the number
During a gout attack, the value can be normal. The S3 guideline writes that values during an attack can be normal or even low, and recommends measuring uric acid again after the inflammation has subsided. Citing a study referenced there, the German general practice guideline from 2023 gives a rate of false normal results of about one third. The NICE guideline recommends repeating the measurement at least two weeks after the attack has settled if gout is strongly suspected and the value during the attack is below 360 µmol/l.
After prolonged fasting, the value can be considerably higher. In a small study of 21 days of water fasting, uric acid more than doubled on average. More on this in the section on the drivers.
Medications shift the value, for example water tablets and low-dose aspirin upwards. More on that shortly.
And your stage of life plays a part. In women, the value shifts with menopause.
Hak and Choi analyzed data from 7,662 women aged 20 and over from the large US health survey NHANES III, taking into account diet, age, body fat, alcohol, kidney function, high blood pressure and water tablets, among other factors.
Women after natural menopause had values 0.34 mg/dl higher than women before menopause, and after surgical menopause 0.36 mg/dl higher. Current hormone therapy was associated with a value 0.24 mg/dl lower.
What this means for you: if your uric acid rises after menopause, this may be partly explained by hormones. A cross-sectional study shows an association, not proof, and it is no reason to start or stop hormone therapy.
Hak AE, Choi HK. Arthritis Res Ther. 2008;10(5):R116. PMID: 18822120 [Cross-sectional, n=7,662]How perimenopause shows up overall and when it begins is explained in Perimenopause: recognizing the symptoms and when it begins.
And when uric acid is too low
That happens too. A review around Ben Salem defines hypouricemia as uric acid of 2.0 mg/dl or less. That is the definition used in this review and not a laboratory cut-off for everyone.
As causes, the paper lists severe liver disease, cancer, impaired reabsorption of uric acid in the kidney tubules, inherited disorders of purine metabolism and medications. Drug-induced hypouricemia most commonly occurs when urate-lowering drugs lower the value more than necessary. Some medications outside gout therapy can also lower the value.
One rare but important form is inherited renal hypouricemia. The review around Nakayama describes that it is often accompanied by complications such as exercise-induced acute kidney injury, meaning kidney damage after strenuous physical exertion. How much a merely slightly low value without an identifiable cause matters, on the other hand, has been little studied.
So a very low value is no reason for joy and no reason for panic. It should be assessed by a doctor. If you take urate-lowering medication, the prescribing practice decides on any adjustment.
And now you know why the same number can mean something different depending on the laboratory, the day, your stage of life and your medication list.
Hyperuricemia is not gout: how often the value turns into a disease
This may be the most important sentence in this article: a high uric acid value is a risk factor and not yet gout. Hyperuricemia only means that uric acid in the blood is high. Gout means that crystals have been deposited and trigger inflammation.
There is a long way in between. As a summary figure, the genetics paper around Vitart states that about 10 percent of people with hyperuricemia develop gout. How strongly this depends on the value is shown by a large analysis from the US.
A team around Dalbeth pooled the individual data of 18,889 people without gout from four large US cohorts, including the Framingham study, and followed them for an average of 11.2 years.
The cumulative incidence of gout over 15 years ranged from 1.1 percent at a baseline uric acid below 6 mg/dl to 49 percent at 10 mg/dl or more. The authors themselves emphasize that only about half of the people with values of 10 mg/dl or more developed clinically evident gout within 15 years.
What this means for you: the higher the value, the more likely gout becomes. Even at very high values, it is not automatic.
Dalbeth N, Phipps-Green A, Frampton C, Neogi T, Taylor WJ, Merriman TR. Ann Rheum Dis. 2018;77(7):1048-1052. PMID: 29463518 [Cohort, pooled individual participant data from 4 cohorts, n=18,889]In its full text, the American College of Rheumatology guideline cites a similar order of magnitude from observational data: of people with asymptomatic hyperuricemia above 9 mg/dl, only 20 percent developed gout within five years.
What symptoms does high uric acid cause?
Usually none. That is the honest answer, and for many a reassuring one. Symptoms arise where uric acid precipitates: as a gout attack in a joint, as gout nodules under the skin or as a uric acid stone in the urinary tract.
Online you often read that uric acid makes you tired, causes water retention or a vague aching in the joints. The research for this article found no reliable study on such complaints as a direct consequence of a high value. That does not prove they do not exist. But it does suggest looking for other causes behind fatigue or swelling as well.
Crystals without an attack: what ultrasound shows
At the start of the TIGER study, a group around Stewart examined 269 people with uric acid of at least 0.48 mmol/l, roughly 8 mg/dl, who had never had a gout attack and had no palpable gout nodules, using standardized ultrasound of the knees, toe base joints and tendons.
In 38.7 percent, at least one definite ultrasound sign of urate deposits was found, such as the typical double contour on the joint cartilage. The amount of deposits was small, however, and the signs were associated with indications of silent inflammation and early joint damage.
What this means for you: crystals can form before a joint hurts. Whether gout follows is what the pending follow-up is meant to show.
Stewart S, Gamble GD, Taylor WJ et al. Ann Rheum Dis. 2026;85(8):1646-1655. PMID: 42002468 [Cohort, baseline cross-sectional analysis, n=269]Ultrasound crystals without symptoms: what it means and what it does not
What it means: the line between lab value and disease is more fluid than previously thought. In some people with high uric acid, something has already been deposited.
What it does not mean: that every such finding needs treatment. With a conditional recommendation, the American College of Rheumatology guideline advises against urate-lowering drugs even when crystals have been detected on ultrasound or dual-energy CT, as long as no gout attacks and no gout nodules have occurred. Whether the new ultrasound data will change this position is an open question.
And now you know why the sentence "You have uric acid, so you have gout" is not true, and why the sentence "Uric acid is just a lab value" falls just as short.
High uric acid, the causes: kidneys, gut, genes, insulin and medications
You eat sensibly, rarely drink alcohol, and meat is not on the table every day. And still uric acid appears with an asterisk on your report. Research offers a well-studied explanation for this.
How much remains depends mainly on the exit
- Production: uric acid arises from the breakdown of the body's own purines and from dietary purines. Fructose metabolism in the liver can also supply uric acid.
- Filter: the kidneys filter uric acid out of the blood but take a large part of it back via transporters such as URAT1 and GLUT9.
- Exit via the kidneys: what is not taken back leaves with the urine. If this exit works sparingly, the blood level can rise even though no more is being produced.
- Exit via the gut: another portion is released into the gut via the transporter ABCG2.
Simplified physiology. That GLUT9, URAT1 and ABCG2 in the kidneys and gut regulate uric acid levels is summarized in the Lancet review around Dalbeth. Like a basin with two drains: the level often rises not because too much is flowing in, but because one drain is stuck.
The kidney as the bottleneck
Perez-Ruiz and colleagues compared 100 people with primary gout and 72 healthy controls using 24-hour urine, uric acid clearance and fractional excretion.
Reduced excretion via the kidneys was the main mechanism of hyperuricemia in gout. Even people who seemed to excrete a lot of uric acid in their 24-hour urine had lower uric acid clearance than the controls.
What this means for you: in most people with gout, overproduction does not appear to be the core issue, but rather kidneys that release uric acid too sparingly.
Perez-Ruiz F, Calabozo M, Erauskin GG, Ruibal A, Herrero-Beites AM. Arthritis Rheum. 2002;47(6):610-3. PMID: 12522834 [Case-control study, n=172]A large study around Qi confirms this picture in 4,873 people with gout. Based on how their kidneys handled uric acid, 60.9 percent showed pure underexcretion, 23.1 percent a mixed type, 8.8 percent renal overload and 7.2 percent an unremarkable pattern. This applies to people with gout, not automatically to every case of hyperuricemia.
This fits with what the S3 guideline writes about kidney function: the frequency of gout rises from 16 percent at an estimated filtration rate of 60 ml/min/1.73 m² or more to 35.6 percent at below 30 ml/min/1.73 m². That is why kidney values belong in every assessment of high uric acid.
The second exit: the gut
A team around Ichida determined the function of the ABCG2 transporter in 644 men with hyperuricemia and examined mice lacking this transporter.
Impaired ABCG2 function reduced excretion outside the kidneys and was a common cause of hyperuricemia. Paradoxically, uric acid in the urine rose at the same time, so those affected looked like overproducers. The mice without the transporter had higher blood levels.
What this means for you: the gut is an exit too, and a urine result can point in the wrong direction.
Ichida K, Matsuo H, Takada T et al. Nat Commun. 2012;3:764. PMID: 22473008 [Cross-sectional in humans plus In vivo, mouse model]Genes shift the starting point
Whether your transporters work generously or sparingly is to a large extent inherited. SLC2A9, also called GLUT9, is one example, ABCG2 a second.
Woodward and colleagues tested urate transport by ABCG2 and its common variant Q141K in the laboratory and studied 14,783 people.
The variant transported 53 percent less uric acid than the normal form. The odds ratio for gout was 1.68 per risk allele, and at least 10 percent of all gout cases in people of European ancestry could be attributed to this variant by calculation.
What this means for you: genes are not destiny, but they can shift your starting point.
Woodward OM, Köttgen A, Coresh J, Boerwinkle E, Guggino WB, Köttgen M. Proc Natl Acad Sci U S A. 2009;106(25):10338-42. PMID: 19506252 [In vitro, transport assay, plus Cohort, n=14,783]Since then, the list has grown long. An analysis around Tin with 457,690 people of different ancestries found 183 gene loci, with the kidneys and liver as the most important target organs. How ancestry and genes shape metabolism overall is covered in Genes, ancestry and metabolism.
Major and colleagues analyzed dietary questionnaires and genetic data from 8,414 men and 8,346 women of European ancestry from five US cohorts, all without kidney disease, gout, urate-lowering drugs or water tablets.
Individual foods were associated with higher values, such as beer, spirits, wine, potatoes, poultry, soft drinks and beef, pork or lamb, and others with lower values, such as eggs, peanuts, skim milk, cheese, brown bread and non-citrus fruit. But dietary patterns each explained at most 0.3 percent of the variation in uric acid, whereas common genetic variants together explained 23.9 percent.
What this means for you: at population level, the plate explains the differences in this analysis far less than many guides suggest. This does not automatically apply to individuals or to attacks in people who already have gout.
Major TJ, Topless RK, Dalbeth N, Merriman TR. BMJ. 2018;363:k3951. PMID: 30305269 [Meta-analysis of cross-sectional data from 5 cohorts, n=16,760]High uric acid despite a healthy diet is not a failure. If you eat sensibly and the value is still high, this may well be down to your kidneys, genes, metabolism or medications; it does not have to be a mistake on your plate.
Food and drink still matter: sweetened drinks and alcohol remain levers, and in gout, peaks in purines and alcohol can set off attacks. But blame drops out of the equation.
Insulin: the bridge to metabolism
This is where it gets interesting from a functional perspective. One of the factors that can narrow the kidney exit is a hormone.
Quiñones Galvan and colleagues raised insulin levels in 20 healthy volunteers in a controlled way while keeping blood sugar constant.
Blood uric acid did not change in this short period, but excretion in the urine fell significantly, coupled with the excretion of sodium. Even at rest, fasting insulin, body weight and diastolic blood pressure were related to uric acid.
What this means for you: a lot of insulin can cause the kidneys to retain uric acid and salt, a bridge between insulin resistance, blood pressure and uric acid.
Quiñones Galvan A, Natali A, Baldi S et al. Am J Physiol. 1995;268(1 Pt 1):E1-5. PMID: 7840165 [Human study, insulin clamp, n=20]This fits with a cross-sectional study around Facchini: in 36 healthy people without diabetes, insulin resistance was closely related to uric acid and inversely related to the kidneys' uric acid clearance. And in the US health survey NHANES III, 62.8 percent of people with gout had metabolic syndrome, compared with 25.4 percent of those without gout.
For me, this is why high uric acid is first of all an invitation to look at blood sugar, insulin, waist circumference, blood pressure and blood lipids. How insulin resistance develops and why it can make weight loss harder is explained in Insulin resistance and weight loss.
Less often, increased production is behind it, for example with rapid cell breakdown during chemotherapy, a separate situation for the treating oncology team.
Uric acid raised by medications: why stopping them is not the answer
No medication is changed on your own because of uric acid
Some medications raise uric acid, and this is well studied. Still, stopping them is not the answer. Water tablets, for example, are used for fluid retention and heart failure, low-dose aspirin often after a heart attack or stroke, beta blockers for high blood pressure and heart rhythm disorders. There are reasons behind them that are weighed against the risk of gout.
Whether a drug that raises uric acid can be replaced is decided by the prescribing doctor, with an eye on the heart, kidneys and blood pressure. Take your medication list to your next appointment and raise uric acid there.
Choi and colleagues compared 24,768 people with new gout against 50,000 controls in UK general practice data and analyzed blood pressure medications in people with hypertension.
The relative risk of new gout was 2.36 for diuretics, 1.48 for beta blockers, 1.24 for ACE inhibitors and 1.29 for angiotensin receptor blockers other than losartan. It was lower for calcium channel blockers at 0.87 and for losartan at 0.81.
What this means for you: blood pressure drugs differ in their relationship to uric acid. These are observational data, and the choice of drug depends on the heart, kidneys and other conditions.
Choi HK, Soriano LC, Zhang Y, Rodríguez LA. BMJ. 2012;344:d8190. PMID: 22240117 [Case-control study, 24,768 cases, 50,000 controls]A meta-analysis of cohort studies around Evans found a relative risk of 2.39 for new gout with diuretics. From this, the S3 guideline derives an expert recommendation addressed to physicians (quoted here in translation): "Medications that raise serum uric acid, in particular loop and thiazide diuretics, should only be used with strict indication; possible alternatives should be sought." As further examples, the guideline names metoprolol and low-dose aspirin. It describes the cholesterol-lowering drug bempedoic acid as contraindicated in known gout. This is addressed to prescribers: anyone taking one of these drugs does not stop it on their own, but raises uric acid with the prescribing practice.
A team around Zhang compared aspirin use in the two days before an attack with attack-free periods in the same 724 people with gout.
Aspirin up to 325 mg daily on two consecutive days was associated with an odds ratio of 1.81 for an attack, and at doses up to 100 mg it was even slightly higher at 1.91. With concurrent use of allopurinol, this effect was no longer seen.
What this means for you: low-dose aspirin can favor attacks. Nevertheless, the American College of Rheumatology guideline conditionally recommends against stopping it when it has been prescribed for a good reason.
Zhang Y, Neogi T, Chen C, Chaisson C, Hunter DJ, Choi H. Ann Rheum Dis. 2014;73(2):385-90. PMID: 23345599 [Case-crossover, n=724]There is also the opposite direction. According to the S3 guideline, an SGLT2 inhibitor in diabetes, kidney or heart failure can "additionally have a lowering effect on the uric acid level" (in translation), and losartan and fenofibrate are also described as lowering uric acid, without evidence of fewer gout attacks. The American guideline gives conditional recommendations to prescribers on this, for example to prefer losartan when choosing a blood pressure drug, but advises against switching to fenofibrate specifically because of gout. These are considerations for the prescribing practice and not a call to change anything yourself.
A medication that raises uric acid is not a mistake in your medication plan, but a trade-off.
The sensible step is therefore a conversation: is there an equivalent alternative for me, and if not, how do we deal with the risk of gout?
And now you know why high uric acid rarely has a single cause, but usually a sum of kidneys, genes, insulin, medications and only then the plate.
Fructose, alcohol, purines, weight, fasting: what drives the value
Anyone searching for "lowering uric acid" quickly lands on long lists of forbidden foods. Red column, green column, done. It is not that simple. Still, there are drivers that are well studied, each presented here with the question of how certain we are.
Fructose and sugar-sweetened drinks
The large cohort studies come from the US. In 46,393 men, drinking two or more sugar-sweetened soft drinks a day over 12 years was associated with a relative risk of gout of 1.85, compared with less than one serving a month. Diet soft drinks showed no association, whereas fruit juice and fructose-rich fruits did.
Choi, Willett and Curhan followed 78,906 women from the Nurses' Health Study over 22 years and documented 778 new cases of gout.
One sugar-sweetened soft drink a day was associated with a relative risk of 1.74, two or more with 2.39. For orange juice, the figures were 1.41 and 2.42. In absolute numbers, this corresponded to 36 and 68 additional cases per 100,000 person-years for soft drinks, and 14 and 47 for orange juice.
What this means for you: the association is clear, the absolute risk remains small. The authors themselves consider the contribution of these drinks to gout in women likely to be modest.
Choi HK, Willett W, Curhan G. JAMA. 2010;304(20):2270-8. PMID: 21068145 [Cohort, n=78,906]Observation is not experiment. That is why controlled feeding trials matter, in which people receive a predefined diet.
Ayoub-Charette and colleagues analyzed 47 controlled feeding trials with 2,763 participants, separated by sugar source and by whether the sugar replaced other calories or was added on top.
Fructose-containing sugars overall raised uric acid only in substitution trials, by 0.16 mg/dl. Sugar-sweetened beverages raised the value both in substitution and in addition trials, while 100 percent fruit juice lowered it in addition trials. Certainty was high for both findings.
What this means for you: fructose itself does not appear to be the main issue, but rather the form in which it comes. Sweetened drinks are the clearest lever here. Avoiding whole fruit across the board cannot be derived from this.
Ayoub-Charette S, Chiavaroli L, Liu Q et al. J Nutr. 2021;151(8):2409-2421. PMID: 34087940 [Meta-analysis of controlled feeding trials, 47 trials, N=2,763]To be honest, not everything fits together when it comes to juice. In the cohort of women, orange juice was associated with more gout, whereas in the feeding trials fruit juice lowered the value. I would rather leave this contradiction standing than smooth it over.
Why fructose is processed differently from glucose in the liver is something I explain in Sugar and fructose. Fructose intolerance in the gut is a separate topic, see Lactose, fructose, sorbitol.
Alcohol, especially beer
Choi and colleagues followed 47,150 men without gout over 12 years.
Compared with non-drinkers, the relative risk rose with the amount, up to 2.53 at 50 g of alcohol or more per day. Beer showed the strongest independent association, with a relative risk of 1.49 per daily 12-ounce serving, roughly 355 ml, while spirits came in at 1.15 per drink. For wine, at 1.04, the association was not significant.
What this means for you: beer was the strongest alcohol factor for new gout here, but that is no all-clear for wine if you already have gout.
Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Lancet. 2004;363(9417):1277-81. PMID: 15094272 [Cohort, n=47,150]In people who already have gout, the picture looks different. In a case-crossover study around Neogi with 724 participants, more than one to two alcoholic drinks in 24 hours were associated with a 1.36-fold and more than two to four with a 1.51-fold risk of an attack, and wine, beer and spirits were each associated with more attacks.
The research found no study on alcohol-free beer with uric acid or gout as an outcome, so I cannot say anything reliable about it. What alcohol can do in the gut even in small amounts is covered in Alcohol and the gut.
Purines: meat yes, vegetables hardly
Purines are the classic among uric acid tips, and the data are more nuanced than the lists. In the same cohort of men as above, the highest fifth of meat intake, compared with the lowest fifth, was associated with a relative risk of gout of 1.41, and the highest fifth for seafood with 1.51. Purine-rich vegetables and total protein intake, on the other hand, were not associated with more gout. Dairy products were associated with a lower risk, relative risk 0.56 for the highest versus the lowest fifth.
That is an observation and not a meal plan, but the statement "purine-rich equals bad" is too crude. For protein needs overall, see How much protein do you need. Organ meats are particularly rich in purines, more on this in Organ meats and bone broth.
A team around Zhang compared purine intake in the two days before an attack with attack-free periods in 633 people with gout.
Compared with the lowest fifth, the odds ratios for an attack in the following fifths were 1.17, 1.38, 2.21 and 4.76. Purines from animal sources showed a stronger association, at 1.42, 1.34, 1.77 and 2.41, than purines from plant sources, at 1.12, 0.99, 1.32 and 1.39.
What this means for you: in gout, a very purine-rich meal, especially from animal sources, can set off an attack. This is about short-term peaks, not a ban on meat.
Zhang Y, Chen C, Choi H et al. Ann Rheum Dis. 2012;71(9):1448-53. PMID: 22648933 [Case-crossover, n=633]Weight
In a meta-analysis of cohort studies around Evans, gout was 2.24 times as likely at a BMI of 30 or more, the study definition of obesity. A systematic review around Nielsen found changes in uric acid with weight loss ranging from minus 168 to plus 30 µmol/l in people with gout and overweight, and six of eight studies showed favorable effects on attacks. The evidence was low to moderate, and shortly after bariatric surgery, attacks tended to increase temporarily.
What matters to me here: weight is not a question of character, and a diet is not a harmless tool. A history of dieting and severe restriction carry their own risks, up to disordered eating, see Understanding eating disorders. How many building blocks interact when it comes to weight is shown in Understanding weight holistically.
Fasting and ketosis: why the value rises
This surprises many people: you eat nothing for days, and uric acid goes up.
A group around Dai accompanied 13 healthy volunteers under medical supervision through 21 days of complete fasting.
Blood ketone bodies rose on average from 0.1 to 6.61 mmol/l. Uric acid rose on average from 385 to 866 µmol/l, that is, to more than double.
What this means for you: long water-only fasting can raise uric acid sharply. The study is very small, has no control group, and is not a recommendation to fast.
Dai Z, Zhang H, Sui X et al. Sci Rep. 2024;14(1):28550. PMID: 39557965 [Intervention study without control group, n=13]Even after ten days of fasting, uric acid rose in 109 people in a study around Wilhelmi de Toledo; no gout attacks occurred in this group, which cannot be transferred to people with gout. The usual explanation: ketone bodies can compete with uric acid for excretion in the kidneys. That is mechanistically plausible, but not supported here by a study of its own.
Animal An interesting counter-movement comes from the laboratory. Goldberg and colleagues found in rats with crystal-induced joint inflammation that a ketogenic diet raised the ketone body beta-hydroxybutyrate and dampened the inflammation, and in cell experiments this ketone body inhibited a central inflammatory signal in immune cells from mice and humans. In humans with gout, this has not been clinically tested and is therefore no argument for a ketogenic diet in gout.
A short eating window in everyday life is something different from ten or 21 days without food, and no comparable uric acid data on intermittent fasting are available here. How fasting can influence blood sugar and insulin resistance is covered in Fasting and blood sugar. If you have gout, discuss longer fasting with your doctor beforehand, because it can change uric acid rapidly. The S3 guideline describes attacks mainly with acute changes in uric acid, for example after rapid weight loss, bariatric surgery, excessive alcohol or high purine intake.
| Driver | Study type | What was shown | Strength |
|---|---|---|---|
| Sugar-sweetened drinks | Feeding trial meta-analysis, cohorts | rise in uric acid, more gout | high |
| Alcohol, especially beer | Cohort, case-crossover | more new gout, more attacks in gout | moderate |
| Meat, seafood | Cohort, case-crossover | more gout, purine peaks before attacks | moderate |
| Overweight | Cohorts, systematic review | more gout, weight loss tends to be favorable | low to moderate |
| Prolonged fasting | small studies without control group | sharp rise in uric acid | low |
| Fruit juice | Cohort versus feeding trials | contradictory | unclear |
| Ketone bodies and crystal inflammation | Animal study, cell experiments | inflammation dampened | laboratory only |
The plate explains the value little, the attack more. At population level, kidneys and genes appear to determine uric acid more strongly than dietary patterns. In people with gout, however, short-term peaks from alcohol, very purine-rich meals or fasting can set off an attack.
If you only have a high value, you do not need a list of bans. If you have gout, it makes more sense to keep an eye on peaks than to fear every ingredient.
And now you know why a list of red and green foods falls short, and where drinks, alcohol and fasting still matter as real levers.
High blood pressure, kidneys, heart: is uric acid culprit or witness?
Perhaps you have read that uric acid is a silent driver of high blood pressure, declining kidney function and heart attacks. And in observational studies, people with high uric acid do indeed have these conditions more often. The only question is whether uric acid causes them or simply happens to be at the scene.
This is not hair-splitting: if uric acid were a cause, lowering it could protect. If it were only a witness, lowering it would likely do little for the heart. Research has approached the question in three ways.
Step one: observation
Li and colleagues collected all meta-analyses on uric acid from observational studies, randomized trials and genetic analyses and assessed 136 different health outcomes.
No association from the observational studies reached the highest level of evidence. Classified as highly suggestive were increased risks of heart failure, high blood pressure, impaired fasting glucose or diabetes, chronic kidney disease and coronary heart disease mortality. High blood pressure and kidney disease were not significant in the genetic analyses. The authors saw convincing evidence of a clear role of uric acid only for gout and kidney stones.
What this means for you: for gout and kidney stones, the role of uric acid is convincingly established. For the heart, blood pressure and kidneys, it is a warning light whose causal role remains open.
Li X, Meng X, Timofeeva M et al. BMJ. 2017;357:j2376. PMID: 28592419 [Review, umbrella review]Step two: genes
Mendelian randomization sounds complicated, but the idea is simple. Some people are born with gene variants that keep their uric acid slightly higher throughout life. That is like a lottery ticket nobody can forge and that has nothing to do with lifestyle. If these people later have heart attacks more often, that points more towards uric acid as a cause. If they do not, that points more towards a witness.
| Study | Question | Result |
|---|---|---|
| Keenan 2016 | Type 2 diabetes, coronary heart disease, stroke, heart failure | no association; gout as positive control: odds ratio 5.84 |
| Jordan 2019 | Kidney function and chronic kidney disease | no causal effect, power above 99 percent |
| Efstathiadou 2019 | Coronary heart disease, heart attack, blood pressure, stroke, cognition | isolated signals, probably genes with multiple effects; no consistent clinically relevant effect |
| Gill 2021 | Coronary heart disease, peripheral artery disease, stroke | odds ratio 1.19, 1.12 and 1.11 per standard deviation; about one third mediated via blood pressure |
| Kleber 2015 (LURIC) | Cardiovascular death, sudden cardiac death | hazard ratio 1.77 and 2.41 per 1 mg/dl of genetically determined uric acid in 3,315 people |
So the genetic studies contradict each other. A large genetic analysis around Tin offers a possible explanation: uric acid shares many genetic foundations with other metabolic and cardiac traits, and the analyses pointed to a considerable role of genes with multiple effects. And for the kidneys, another interpretation suggests itself: a kidney that works less well excretes less uric acid. High uric acid would then be more a consequence than a cause. That is a plausible explanation, not proof.
Step three: treatment trials
In the end, what counts is whether lowering it changes anything. Large trials now exist here, and their results for symptom-free hyperuricemia are sobering.
| Study | Who | Result |
|---|---|---|
| Feig 2008, RCT | 30 adolescents with newly diagnosed high blood pressure | blood pressure fell, 20 of 30 normotensive versus 1 on placebo; preliminary according to the authors |
| Gaffo 2021, RCT | 99 young adults with elevated blood pressure | systolic blood pressure unchanged, vascular function improved |
| Cochrane, Gois 2020 | 3 RCTs, 211 people with high blood pressure | data insufficient to establish a reduction in blood pressure |
| CKD-FIX, Badve 2020 | 369 people without gout with stage 3 or 4 kidney disease | no difference in loss of kidney function; stopped early |
| PERL, Doria 2020 | 530 people with type 1 diabetes and kidney damage | no clinically meaningful benefit; albumin excretion after washout 40 percent higher on allopurinol |
| FREED, Kojima 2019, open-label | 1,070 older people in Japan with hyperuricemia and risk factors | combined outcome less frequent, hazard ratio 0.750, mainly less worsening of kidney function |
| Sapankaew 2022, network meta-analysis | 23 RCTs in asymptomatic hyperuricemia | fewer renal events, no advantage for other outcomes |
| ALL-HEART, Mackenzie 2022, open-label | 5,721 people aged 60 and over with coronary heart disease without gout | no difference in heart attack, stroke or cardiovascular death, hazard ratio 1.04 |
So the large Western trials found no hard benefit for the kidneys or the heart. The Japanese FREED trial and the network meta-analysis of 23 trials are more positive, especially for the kidneys. Important for ALL-HEART: high uric acid was not an inclusion criterion there.
Two serious camps
The American College of Rheumatology guideline conditionally recommends against urate-lowering drugs in symptom-free hyperuricemia, explicitly including chronic kidney disease, cardiovascular disease, kidney stones or high blood pressure.
The Japanese guideline on hyperuricemia and gout, by contrast, according to a review by Japanese authors around Hisatome, recommends drug treatment of hyperuricemia in chronic kidney disease and relies in part on FREED. The original guideline could not be checked for this article.
Both sides work with data; neither is an outsider. The German S3 guideline does not comment on symptom-free hyperuricemia. Incidentally, the question of whether a value is a marker or a cause accompanies cardiology with other values too; one example is the debate in Cholesterol: firefighter or fire.
Based on current data, high uric acid without gout is above all a warning light on the dashboard. It is worth checking what is going on underneath: blood pressure, blood sugar, kidney function, weight, drinks, medications.
Switching off the warning light with a tablet did not protect the heart and kidneys in the large Western trials. This concerns people without gout and is no reason to end a prescribed gout treatment. Addressing the causes underneath still makes sense, because they are risks in their own right.
And now you know why the same body of evidence leads to a different recommendation in Japan than in the US, and why neither contradicts your own curiosity about the causes.
Gout attack and gout: symptoms, medical treatment and what the guidelines say
It often starts at night. You wake up, and your big toe is burning. Within a few hours the joint is red, hot and swollen, and even the duvet is too much.
The British NICE guideline describes the typical suspicion in exactly this way: rapid onset, often overnight, severe pain with redness and swelling in one or both big toe base joints. But the midfoot, ankle, knee, hand, wrist or elbow can also be affected. And it explicitly recommends considering septic arthritis, calcium pyrophosphate deposition and inflammatory joint diseases.
That is exactly why a gout attack should be looked at by a doctor. Not every hot joint is gout, and mistaking it for a joint infection can be dangerous. The German general practice guideline points out that general well-being is usually undisturbed during a gout attack, whereas in advanced septic arthritis it is typically worse. The red flags are in the box at the very top.
Gout is also not a series of isolated accidents. The Lancet review around Dalbeth describes it as a chronic disease, even if it shows itself in flares. And an attack is more than a painful toe: in English general practice data, a team around Cipolletta found that heart attacks and strokes occurred more often in the 60 days after a gout attack than in comparison periods of the same people, with an adjusted incidence rate ratio of 1.89. That is an observation, but a good reason to take attacks seriously.
The German S3 guideline: clear on the attack, divided on the target value
Since its revision in 2024, Germany has an interdisciplinary S3 guideline on gout, led by the German Society for Rheumatology and Clinical Immunology, with general practice among the participating disciplines. The most important recommendations, quoted in translation and deliberately without doses. The German wording "soll" (the strongest level) is rendered as "shall", "sollte" as "should" and "kann" as "can":
- Attack, recommendation 3.1, recommendation grade A: "Treatment of an acute gout attack shall be carried out promptly with colchicine, glucocorticoids or non-steroidal anti-inflammatory drugs (NSAIDs) (in alphabetical order) as first-choice agents." The choice shall be guided by concomitant medication, comorbidities and contraindications.
- No improvement, recommendation 3.5: if symptoms do not improve within 24 to 72 hours, "a re-evaluation and, if necessary, an adjustment of therapy should take place".
- Supportive, recommendation 3.6, recommendation grade B: rest, elevation and cooling "should be applied supportively".
- First attack, recommendation 4.1, recommendation grade 0: "At the first gout attack, all therapy options should be discussed with the patient in order to prevent further gout attacks."
- Long-term lowering, recommendation 4.2, recommendation grade 0: therapy with a xanthine oxidase inhibitor should be started in the case of a limiting or impairing attack, more than one gout attack per year or tophaceous gout.
- Target value, recommendation 4.5, recommendation grade 0: "In patients with diagnosed gout on XOI therapy, a serum uric acid of <6 mg/dl should be achieved." In tophaceous gout, "a target serum uric acid of <5 mg/dl can be considered" (4.6, recommendation grade 0).
- Cardiovascular comorbidity, recommendation 5, recommendation grade B: treatment should preferably be with allopurinol, alternatively with febuxostat.
One sentence from the guideline's rationale is particularly important to me, because it contradicts a common impulse: "Urate-lowering therapy that has already been started should not be interrupted because of a renewed gout attack, as fluctuations in the serum uric acid level can in turn favor gout attacks." If you have an attack while on treatment, discuss how to proceed with your treating practice.
And it is honest about the patience required: according to the rationale, significant effects on the number of attacks appear after 12 months at the earliest.
Treat-to-target: rheumatology and general practice look at different people
The recommendation on the target value below 6 mg/dl received 81 percent agreement. The German College of General Practitioners and Family Physicians (DEGAM) submitted a dissenting vote: it argues for a patient-centered approach adapted to individual risk and gout burden and states: "A T2T strategy should not be applied as a matter of principle." As reasons, it names an unknown balance of benefit and harm and possible overtreatment.
In favor of the target value is an analysis of two randomized trials around Stamp with 588 people: those who had reached the target value had an attack less often between month 12 and 24, 27 versus 64 percent. However, this was not a randomized comparison of the strategies. A large cohort analysis around Cipolletta with 109,504 people with gout also found that reaching the target value was associated with slightly fewer major cardiovascular events, hazard ratio 0.91, likewise without randomization.
Both positions stand in the same guideline. I also read two perspectives in this: rheumatology clinics tend to see more severe cases, general practices tend to see people with infrequent attacks and many other issues. That is an honest difference of opinion and not a turf war.
In the CARES trial around White, 6,190 people with gout and relevant pre-existing cardiovascular disease received febuxostat or allopurinol. For the combined outcome, febuxostat was noninferior, but all-cause mortality and cardiovascular mortality were higher, with hazard ratios of 1.22 and 1.34. 56.6 percent discontinued the study medication. According to the S3 guideline, a Rote-Hand-Brief (a German direct healthcare professional communication on drug safety) followed in 2019.
The FAST trial around Mackenzie with 6,128 people aged 60 and over on allopurinol and with at least one additional risk factor found febuxostat noninferior, adjusted hazard ratio 0.85, and no higher mortality.
What this means for you: the two trials contradict each other and, according to the S3 guideline, have serious limitations. The guideline therefore recommends allopurinol as the preferred option in cardiovascular disease. Questions about a current drug belong with the prescribing practice.
White WB, Saag KG, Becker MA et al. N Engl J Med. 2018;378(13):1200-1210. PMID: 29527974 [RCT, n=6,190] · Mackenzie IS, Ford I, Nuki G et al. Lancet. 2020;396(10264):1745-1757. PMID: 33181081 [RCT, n=6,128]What the international guidelines say
| Situation | S3 DGRh 2024 | ACR 2020 | EULAR 2016 | NICE 2022 |
|---|---|---|---|---|
| Starting long-term lowering | with a limiting attack, more than one attack per year or tophi (0) | strong with tophi, radiographic damage or frequent attacks; after a first attack conditionally against, with exceptions | consider from the first presentation | with multiple or troublesome attacks, kidney disease stages 3 to 5, diuretics, tophi, chronic arthritis |
| Target value on therapy | below 6 mg/dl (0), with tophi consider below 5 mg/dl (0); DEGAM dissenting vote | below 6 mg/dl (strong) | below 6 mg/dl, in severe gout below 5 mg/dl | below 360 µmol/l, with tophi or ongoing attacks consider below 300 µmol/l |
| Symptom-free hyperuricemia | no statement | conditionally against drug lowering | no treatment recommendation in the text reviewed | no treatment recommendation in the text reviewed |
| Diet | balanced, less meat, alcohol, fructose "can" (0); no specific diet supported | limit alcohol, purines and corn syrup (conditional); against vitamin C supplementation (conditional) | education and a non-pharmacological approach named, details not checked (only the abstract was accessible) | no specific diet sufficiently supported |
And symptom-free hyperuricemia?
This is where the guidelines diverge most. The American College of Rheumatology guideline states: for people with asymptomatic hyperuricemia, meaning uric acid above 6.8 mg/dl without previous gout attacks or gout nodules, starting drug-based urate lowering with allopurinol, febuxostat or probenecid is conditionally not recommended. The rationale states that in the trials, fewer than 1 percent on treatment and 5 percent on placebo developed gout, and that 24 people would need to be treated for three years to prevent a single first gout attack.
The German S3 guideline applies to people with gout and contains neither a recommendation nor a statement on symptom-free hyperuricemia. The earlier German general practice guideline on chronic gout, now expired and incorporated into the S3, stated (in translation): "The current evidence does not allow a recommendation on the treatment of asymptomatic hyperuricemia." It also advised against routine measurement of uric acid without a specific reason. EULAR and NICE contain no treatment recommendation for symptom-free hyperuricemia in the texts reviewed. According to the review around Hisatome, the Japanese guideline recommends drug treatment in chronic kidney disease.
In gout, uric acid is the target; without gout, it is the signpost. For people with gout, the guidelines recommend medically guided treatment tailored to their own risk, and according to the S3 guideline it should not be interrupted because of a renewed attack.
If you only have a high value, Western guidelines do not recommend a tablet. For these people, the value is above all a reason to ask about kidneys, insulin, blood pressure, drinks, alcohol and medications.
And now you know why a gout attack belongs in a doctor's practice, why the treatment afterwards requires patience and why a high value without symptoms does not automatically mean a tablet.
Lowering uric acid: what you can influence yourself, sorted by evidence
Now comes the part you may have been looking for first. I will start with an honest expectation.
For the S3 guideline, the German Institute for Quality and Efficiency in Health Care (IQWiG) evaluated randomized trials on lifestyle in gout. Of ten trials, eight compared an active measure with placebo, no treatment or usual care. Six trials reported on the outcome of gout attacks: five of them, with omega-3, tart cherry products, turmeric or skim milk powder, had no significant results or very low quality. Only a small pilot study with a probiotic and 30 participants showed significant effects. Because of its limitations and a high risk of reporting bias, the guideline group did not use it for recommendations. The guideline therefore phrases things cautiously, recommendation 7.1, recommendation grade 0 (in translation): "A healthy, balanced diet with reduced meat consumption, a plant-based emphasis, reduced alcohol consumption and reduction of fructose-enriched foods can be recommended to patients with gout. There is no evidence-based recommendation for a specific diet that reduces gout attacks."
Added to this is recommendation 7.2 with recommendation grade B: education that obesity, overweight and excessive alcohol consumption increase the risk of gout attacks "should take place". The NICE guideline says something similar: there is not enough evidence that any particular diet prevents attacks or lowers uric acid.
So the levers in everyday life are real, but smaller than in many guides, and they do not replace medical gout therapy.
| Lever | What the studies show | Assessment |
|---|---|---|
| Replace sweetened drinks with unsweetened ones | Feeding trials: rise with high certainty (Ayoub-Charette 2021); cohorts: more gout (Choi 2008, 2010) | clearest dietary lever |
| Limit alcohol, especially beer | Cohort: more gout (Choi 2004); in gout, every type of alcohol associated with attacks (Neogi 2014); ACR conditional; S3 7.2 (B) | well founded |
| Weight in overweight | Cohorts, systematic review, low to moderate quality (Evans 2018, Nielsen 2017); ACR conditional | tends to be favorable, without rapid weight loss |
| Limit purine-rich animal meals | Cohort, case-crossover (Choi 2004, Zhang 2012); ACR conditional | mainly against peaks in gout |
| DASH dietary pattern | randomized feeding trial: minus 0.35 mg/dl; from a baseline of 7 mg/dl minus 1.29 mg/dl in only 8 people (Juraschek 2016) | plausible, small data base at high values |
| Dairy products | Cohort: relative risk 0.56 (Choi 2004); enriched skim milk powder with fewer attacks in a proof-of-concept RCT with 120 people (Dalbeth 2012); ACR: no recommendation | a signal, not proof |
| Coffee | Cohort: relative risk 0.60 at 4 to 5 and 0.41 at 6 or more cups (Choi 2007); cross-sectional: lower values (Choi 2007); no RCT | observation, no reason to start |
| Vitamin C as a supplement | Meta-analysis: minus 0.35 mg/dl at baseline levels of 2.9 to 7.0 mg/dl, high heterogeneity (Juraschek 2011); clinically insignificant in gout (Stamp 2013); ACR conditionally against | not recommended in gout |
| Cherries, cherry concentrate | Case-crossover: fewer attacks (Zhang 2012); RCT: no effect over 28 days (Stamp 2020); IQWiG, ACR: not robust | unproven |
| Apple cider vinegar, baking soda, teas | no studies on uric acid or gout found | not studied |
| Exercise | S3: no data specific to gout, general principles apply | sensible for metabolism, open for uric acid |
Vitamin C and cherries: two home remedies put to the test
Juraschek and colleagues pooled 13 randomized trials with 556 participants, with baseline levels between 2.9 and 7.0 mg/dl, with a median study dose of 500 mg daily over a median of 30 days: uric acid fell by 0.35 mg/dl on average, with widely varying individual results. In a randomized pilot study led by Stamp with 40 people with gout, some received the same study dose for 8 weeks while the others started allopurinol or had their allopurinol dose increased: on vitamin C the value fell by 0.23 mg/dl, compared with 1.9 mg/dl when allopurinol was started or increased.
What this means for you: in this pilot study, vitamin C barely moved the value in gout in a clinically meaningful way. The American guideline conditionally recommends against vitamin C supplementation in gout.
Juraschek SP, Miller ER, Gelber AC. Arthritis Care Res (Hoboken). 2011;63(9):1295-306. PMID: 21671418 [Meta-analysis, 13 RCTs, n=556] · Stamp LK, O'Donnell JL, Frampton C et al. Arthritis Rheum. 2013;65(6):1636-42. PMID: 23681955 [RCT, pilot study, n=40]In 633 people with gout, cherries in the preceding two days were associated with a 35 percent lower risk of an attack, odds ratio 0.65 (Zhang). In a randomized trial around Stamp with 50 people with gout, tart cherry concentrate over 28 days changed neither uric acid nor the frequency of attacks.
What this means for you: if you like cherries, enjoy them. As a means of lowering uric acid, they are not supported by evidence.
Zhang Y, Neogi T, Chen C et al. Arthritis Rheum. 2012;64(12):4004-11. PMID: 23023818 [Case-crossover, n=633] · Stamp LK, Chapman P, Frampton C et al. Rheumatology (Oxford). 2020;59(9):2374-2380. PMID: 31891407 [RCT, n=50]Home remedy lists promise more than the studies deliver. Apple cider vinegar, baking soda and teas have not been studied for uric acid, and cherries and vitamin C have disappointed in trials. That is not bad news. It saves you money and hope that you can put into levers that actually have data.
This is an approach and not a study result. With high uric acid without gout, I first ask about kidney values, blood sugar and signs of insulin resistance, blood pressure and waist circumference, the medication list, drinks and alcohol, and any history of joint complaints. The thinking behind this is that high uric acid without gout can say more about metabolism than about the joints.
With confirmed gout, the order is different. Then guideline-based treatment comes first, and lifestyle is added alongside it, not instead of it.
And perhaps that is exactly where the freedom lies with this topic. It is not about fighting a number or never drinking a beer again. It is about improving your chances of quiet nights without a burning toe and understanding your metabolism well enough that the lab report frightens you less.
Three levers you can start with
- Replace sweetened drinks with unsweetened ones. This is the dietary lever with the clearest evidence for the uric acid value.
- Clearly limit alcohol, especially beer. If you have gout, avoid drinking peaks in particular, because in one study every type of alcohol was associated with attacks in people with gout.
- Discuss your medication list and kidney values with your doctor. Not to stop anything, but to understand what co-determines your value.
If you would like not only to read but to interpret your values together: below this article you will find the option to book an appointment.
And now you know why three calm levers can achieve more than a long list of bans.
Frequently asked questions about uric acid
At what level is uric acid too high?
There is no single normal value for everyone; according to the German general practice guideline, laboratory reference ranges differ considerably. According to the German S3 guideline, uric acid can crystallize from a zone of around 6.8 mg/dl, depending on temperature and tissue. Your own value is best interpreted together with your doctor.
What symptoms does high uric acid cause, including in women?
Usually none. Symptoms arise from crystals: as a gout attack, gout nodules (tophi) or a uric acid stone. No reliable study was found for fatigue or water retention as a direct consequence. In a US cross-sectional study, women after natural menopause had values that were on average 0.34 mg/dl higher.
Uric acid too high but no gout: what to do?
It makes sense to look at kidney values, blood sugar, blood pressure, the medication list, sweetened drinks and alcohol. The American College of Rheumatology guideline conditionally recommends against urate-lowering drugs in this situation; the German S3 guideline does not comment. Replacing sweetened drinks and limiting alcohol are the levers with the clearest evidence.
Does high uric acid without symptoms need to be treated with tablets?
The American College of Rheumatology guideline conditionally advises against it, including in heart or kidney disease. CKD-FIX, PERL and ALL-HEART found no benefit of allopurinol for the kidneys or heart in people without gout. According to a review, the Japanese guideline recommends treatment in chronic kidney disease. The decision belongs in a conversation with your doctor.
Which foods raise uric acid?
In observational studies, sugar-sweetened drinks, beer, spirits, a lot of meat and seafood were associated with more gout, purine-rich vegetables were not. In feeding trials, sweetened drinks raised uric acid with high certainty. In a large analysis, however, genes explained the differences in the value far more than dietary patterns did.
Can uric acid be lowered with home remedies?
The evidence is thin. Cherries were associated with fewer attacks, but a tart cherry concentrate did not lower uric acid in a randomized trial. Vitamin C barely lowered the value in a clinically meaningful way in people with gout. Apple cider vinegar, baking soda or teas have not been studied, and none of them replaces medical gout treatment.
Can I drink coffee if my uric acid is high?
In a large cohort of men, drinking a lot of coffee was associated with less gout, and coffee drinkers had slightly lower values in a cross-sectional study. Randomized trials are lacking. Based on these observational data, nothing speaks against your usual cup from a uric acid perspective, but it is no reason to start.
Which medications raise uric acid?
Well studied are loop and thiazide diuretics and low-dose aspirin, and in observational data also beta blockers and ACE inhibitors. Do not stop any of them on your own. The American College of Rheumatology guideline conditionally recommends against stopping appropriately prescribed aspirin because of gout. Whether a drug can be replaced is decided by the prescribing doctor.
Why does uric acid rise during fasting or a ketogenic diet?
According to the common explanation, ketone bodies can compete with uric acid for excretion in the kidneys. In a small study of 21 days of water fasting, uric acid rose on average from 385 to 866 µmol/l. Short breaks between meals are not comparable. If you have gout, discuss longer fasting with your doctor beforehand.
Can I have a gout attack even with normal uric acid?
Yes. According to the German S3 guideline, uric acid can be normal or even low during an attack, and the German general practice guideline cites about one third false normal results. NICE recommends repeating the measurement at least two weeks after the attack has settled if gout is strongly suspected and the value is low.
How do I recognize a gout attack in the foot and what should I do?
Typical signs are a rapid onset, often at night, severe pain, redness and swelling at the base of the big toe. Have the attack treated by a doctor promptly, and always the first one. With fever, chills or feeling unwell, the joint must be seen the same day to rule out a septic joint infection.
What medications are available for gout?
For the attack, the German S3 guideline names colchicine, glucocorticoids or non-steroidal anti-inflammatory drugs as first choice, recommendation grade A. For long-term lowering, xanthine oxidase inhibitors are used above all, with allopurinol preferred in cardiovascular disease. Drug and dose depend on kidneys, other conditions and medications and belong in a medical prescription.
Is high uric acid dangerous for the heart and kidneys?
In observational studies, high uric acid is associated with high blood pressure, kidney and heart disease; whether it causes them is disputed. Allopurinol in people without gout did not protect the kidneys or the heart in large Western trials. A clear role is convincingly established only for gout and kidney stones.
What does low uric acid mean?
One review defines hypouricemia as 2.0 mg/dl or less. Causes can include urate-lowering drugs that lower more than necessary, severe liver disease or cancer, or inherited disorders in the kidney. In the inherited form, acute kidney failure after strenuous exercise has been described. A very low value should be assessed by a doctor.
Where uric acid connects to the rest of your metabolism
Uric acid rarely stands alone. It is linked to the liver and fructose, to insulin and weight, to alcohol, to genes and to your stage of life. Here are ten paths that lead on from this article.
Sugar and fructose: the liver is where it happens
Why fructose is processed differently from glucose.
Blood sugar and insulinInsulin resistance and weight loss
How insulin resistance develops and why it can be so persistent when it comes to weight.
If you fastFasting and blood sugar
What intermittent fasting can do in insulin resistance.
If alcohol plays a roleAlcohol and the gut
What even small amounts of alcohol can change in the gut, beyond uric acid.
Dairy productsAre dairy products healthy?
An assessment of pros and cons that goes beyond the gout question.
CoffeeCoffee, cortisol, adenosine and hormones
What your morning cup can do beyond uric acid.
When genes come into playGenes, ancestry and metabolism
Why not everyone needs the same diet and genes shift the starting point.
Marker or causeCholesterol: firefighter or fire
The same basic question as with uric acid, told through the example of another blood value.
If weight is an issueUnderstanding weight holistically
All the building blocks at a glance, without blame and without a quick diet.
MenopausePerimenopause: symptoms and onset
How you can recognize perimenopause and when it can begin.
Scientific sources
- Tausche AK, Schneidereit T, Napierala H, et al. [Diagnostics and treatment of gout: S3 guideline of the German Society for Rheumatology and Clinical Immunology (DGRh, lead management) and participating professional societies]. Z Rheumatol. 2025;84(Suppl 2):51-81. AWMF register 060-005, version 2.1, revised 27 August 2024. PMID: 40689975 · DOI: 10.1007/s00393-025-01634-y [Guideline, S3]
- Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM). Diagnostik und Therapie der akuten Gicht (Diagnosis and treatment of acute gout). S2e guideline, AWMF register no. 053-032b, version of 18 August 2023. degam.de [Guideline, S2e, no DOI]
- Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM). Häufige Gichtanfälle und chronische Gicht (Frequent gout attacks and chronic gout). S2e guideline, AWMF register no. 053-032a, version of 16 March 2021, expired since 06/2024. degam.de [Guideline, expired, historical only, no DOI]
- FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020;72(6):744-760. PMID: 32391934 · DOI: 10.1002/acr.24180 [Guideline, ACR]
- Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. PMID: 27457514 · DOI: 10.1136/annrheumdis-2016-209707 [Guideline, EULAR]
- Neilson J, Bonnon A, Dickson A, et al. Gout: diagnosis and management, summary of NICE guidance. BMJ. 2022;378:o1754. PMID: 36041743 · DOI: 10.1136/bmj.o1754. Full guideline: National Institute for Health and Care Excellence, NICE guideline NG219, 2022, nice.org.uk [Guideline, NICE]
- Hisatome I, Li P, Miake J, et al. Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease: Japanese Guideline on the Management of Asymptomatic Hyperuricemia. Circ J. 2021;85(2):130-138. PMID: 33342914 · DOI: 10.1253/circj.CJ-20-0406 [Review, describes the Japanese guideline]
- Vitart V, Rudan I, Hayward C, et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet. 2008;40(4):437-42. PMID: 18327257 · DOI: 10.1038/ng.106 [Genome-wide association study with in vitro component]
- Kratzer JT, Lanaspa MA, Murphy MN, et al. Evolutionary history and metabolic insights of ancient mammalian uricases. Proc Natl Acad Sci U S A. 2014;111(10):3763-8. PMID: 24550457 · DOI: 10.1073/pnas.1320393111 [In vitro, reconstructed enzymes and cell culture]
- Ames BN, Cathcart R, Schwiers E, et al. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A. 1981;78(11):6858-62. PMID: 6947260 · DOI: 10.1073/pnas.78.11.6858 [In vitro, hypothesis]
- Nakayama A, Kurajoh M, Toyoda Y, et al. Dysuricemia. Biomedicines. 2023;11(12):3169. PMID: 38137389 · DOI: 10.3390/biomedicines11123169 [Review]
- Dalbeth N, Phipps-Green A, Frampton C, et al. Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis. Ann Rheum Dis. 2018;77(7):1048-1052. PMID: 29463518 · DOI: 10.1136/annrheumdis-2017-212288 [Cohort, pooled individual participant data from 4 cohorts, n=18,889]
- Stewart S, Gamble GD, Taylor WJ, et al. Musculoskeletal ultrasound findings in people with asymptomatic hyperuricemia: baseline analysis from the Transitions in Gout Research (TIGER) study using the OMERACT gout ultrasound semiquantitative scoring system. Ann Rheum Dis. 2026;85(8):1646-1655. PMID: 42002468 · DOI: 10.1016/j.ard.2026.03.021 [Cohort, baseline cross-sectional analysis, n=269]
- Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis. 2008;67(7):960-6. PMID: 17981913 · DOI: 10.1136/ard.2007.076232 [Real-world data, retrospective analysis of practice data]
- Hak AE, Choi HK. Menopause, postmenopausal hormone use and serum uric acid levels in US women: the Third National Health and Nutrition Examination Survey. Arthritis Res Ther. 2008;10(5):R116. PMID: 18822120 · DOI: 10.1186/ar2519 [Cross-sectional, n=7,662]
- Ben Salem C, Agrebi M, Sahnoun D, et al. Drug-Induced Hypouricemia. Drug Saf. 2025;48(2):129-142. PMID: 39289314 · DOI: 10.1007/s40264-024-01485-7 [Review]
- Dalbeth N, Gosling AL, Gaffo A, et al. Gout. Lancet. 2021;397(10287):1843-1855. PMID: 33798500 · DOI: 10.1016/S0140-6736(21)00569-9 [Review, seminar]
- Perez-Ruiz F, Calabozo M, Erauskin GG, et al. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum. 2002;47(6):610-3. PMID: 12522834 · DOI: 10.1002/art.10792 [Case-control study, n=172]
- Qi H, Sun M, Terkeltaub R, et al. Hyperuricemia Subtypes Classified According to Renal Uric Acid Handling Manifesting Distinct Phenotypic and Genetic Profiles in People With Gout. Arthritis Rheumatol. 2024;76(7):1130-1140. PMID: 38412854 · DOI: 10.1002/art.42838 [Cross-sectional, n=4,873]
- Ichida K, Matsuo H, Takada T, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun. 2012;3:764. PMID: 22473008 · DOI: 10.1038/ncomms1756 [Cross-sectional in humans plus In vivo, mouse model]
- Woodward OM, Köttgen A, Coresh J, et al. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci U S A. 2009;106(25):10338-42. PMID: 19506252 · DOI: 10.1073/pnas.0901249106 [In vitro, transport assay, plus Cohort, n=14,783]
- Tin A, Marten J, Halperin Kuhns VL, et al. Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels. Nat Genet. 2019;51(10):1459-1474. PMID: 31578528 · DOI: 10.1038/s41588-019-0504-x [Genome-wide association study, n=457,690]
- Major TJ, Topless RK, Dalbeth N, et al. Evaluation of the diet wide contribution to serum urate levels: meta-analysis of population based cohorts. BMJ. 2018;363:k3951. PMID: 30305269 · DOI: 10.1136/bmj.k3951 [Meta-analysis of cross-sectional data from 5 cohorts, n=16,760]
- Quiñones Galvan A, Natali A, Baldi S, et al. Effect of insulin on uric acid excretion in humans. Am J Physiol. 1995;268(1 Pt 1):E1-5. PMID: 7840165 · DOI: 10.1152/ajpendo.1995.268.1.E1 [Human study, insulin clamp, n=20]
- Facchini F, Chen YD, Hollenbeck CB, et al. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA. 1991;266(21):3008-11. PMID: 1820474 · DOI (Crossref): 10.1001/jama.1991.03470210076036 [Cross-sectional, n=36]
- Choi HK, Ford ES, Li C, et al. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109-15. PMID: 17266099 · DOI: 10.1002/art.22466 [Cross-sectional, n=8,807]
- Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ. 2008;336(7639):309-12. PMID: 18244959 · DOI: 10.1136/bmj.39449.819271.BE [Cohort, n=46,393]
- Choi HK, Willett W, Curhan G. Fructose-rich beverages and risk of gout in women. JAMA. 2010;304(20):2270-8. PMID: 21068145 · DOI: 10.1001/jama.2010.1638 [Cohort, n=78,906]
- Ayoub-Charette S, Chiavaroli L, Liu Q, et al. Different Food Sources of Fructose-Containing Sugars and Fasting Blood Uric Acid Levels: A Systematic Review and Meta-Analysis of Controlled Feeding Trials. J Nutr. 2021;151(8):2409-2421. PMID: 34087940 · DOI: 10.1093/jn/nxab144 [Meta-analysis of controlled feeding trials, 47 trials, N=2,763]
- Choi HK, Atkinson K, Karlson EW, et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet. 2004;363(9417):1277-81. PMID: 15094272 · DOI: 10.1016/S0140-6736(04)16000-5 [Cohort, n=47,150]
- Neogi T, Chen C, Niu J, et al. Alcohol quantity and type on risk of recurrent gout attacks: an internet-based case-crossover study. Am J Med. 2014;127(4):311-8. PMID: 24440541 · DOI: 10.1016/j.amjmed.2013.12.019 [Case-crossover, n=724]
- Choi HK, Atkinson K, Karlson EW, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004;350(11):1093-103. PMID: 15014182 · DOI: 10.1056/NEJMoa035700 [Cohort, n=47,150]
- Zhang Y, Chen C, Choi H, et al. Purine-rich foods intake and recurrent gout attacks. Ann Rheum Dis. 2012;71(9):1448-53. PMID: 22648933 · DOI: 10.1136/annrheumdis-2011-201215 [Case-crossover, n=633]
- Evans PL, Prior JA, Belcher J, et al. Obesity, hypertension and diuretic use as risk factors for incident gout: a systematic review and meta-analysis of cohort studies. Arthritis Res Ther. 2018;20(1):136. PMID: 29976236 · DOI: 10.1186/s13075-018-1612-1 [Meta-analysis of cohort studies]
- Nielsen SM, Bartels EM, Henriksen M, et al. Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. Ann Rheum Dis. 2017;76(11):1870-1882. PMID: 28866649 · DOI: 10.1136/annrheumdis-2017-211472 [Systematic Review, 10 studies]
- Dai Z, Zhang H, Sui X, et al. Analysis of physiological and biochemical changes and metabolic shifts during 21-Day fasting hypometabolism. Sci Rep. 2024;14(1):28550. PMID: 39557965 · DOI: 10.1038/s41598-024-80049-2 [Intervention study without control group, n=13]
- Wilhelmi de Toledo F, Grundler F, Goutzourelas N, et al. Influence of Long-Term Fasting on Blood Redox Status in Humans. Antioxidants (Basel). 2020;9(6):496. PMID: 32517172 · DOI: 10.3390/antiox9060496 [Observational study without control group, n=109]
- Goldberg EL, Asher JL, Molony RD, et al. β-Hydroxybutyrate Deactivates Neutrophil NLRP3 Inflammasome to Relieve Gout Flares. Cell Rep. 2017;18(9):2077-2087. PMID: 28249154 · DOI: 10.1016/j.celrep.2017.02.004 [In vivo, rats and mice, plus cell experiments]
- Choi HK, Soriano LC, Zhang Y, et al. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ. 2012;344:d8190. PMID: 22240117 · DOI: 10.1136/bmj.d8190 [Case-control study, 24,768 cases, 50,000 controls]
- Zhang Y, Neogi T, Chen C, et al. Low-dose aspirin use and recurrent gout attacks. Ann Rheum Dis. 2014;73(2):385-90. PMID: 23345599 · DOI: 10.1136/annrheumdis-2012-202589 [Case-crossover, n=724]
- Li X, Meng X, Timofeeva M, et al. Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies. BMJ. 2017;357:j2376. PMID: 28592419 · DOI: 10.1136/bmj.j2376 [Review, umbrella review]
- Keenan T, Zhao W, Rasheed A, et al. Causal Assessment of Serum Urate Levels in Cardiometabolic Diseases Through a Mendelian Randomization Study. J Am Coll Cardiol. 2016;67(4):407-416. PMID: 26821629 · DOI: 10.1016/j.jacc.2015.10.086 [Mendelian randomization]
- Jordan DM, Choi HK, Verbanck M, et al. No causal effects of serum urate levels on the risk of chronic kidney disease: A Mendelian randomization study. PLoS Med. 2019;16(1):e1002725. PMID: 30645594 · DOI: 10.1371/journal.pmed.1002725 [Mendelian randomization]
- Efstathiadou A, Gill D, McGrane F, et al. Genetically Determined Uric Acid and the Risk of Cardiovascular and Neurovascular Diseases: A Mendelian Randomization Study of Outcomes Investigated in Randomized Trials. J Am Heart Assoc. 2019;8(17):e012738. PMID: 31438759 · DOI: 10.1161/JAHA.119.012738 [Mendelian randomization]
- Gill D, Cameron AC, Burgess S, et al. Urate, Blood Pressure, and Cardiovascular Disease: Evidence From Mendelian Randomization and Meta-Analysis of Clinical Trials. Hypertension. 2021;77(2):383-392. PMID: 33356394 · DOI: 10.1161/HYPERTENSIONAHA.120.16547 [Mendelian randomization plus meta-analysis of RCTs]
- Kleber ME, Delgado G, Grammer TB, et al. Uric Acid and Cardiovascular Events: A Mendelian Randomization Study. J Am Soc Nephrol. 2015;26(11):2831-8. PMID: 25788527 · DOI: 10.1681/ASN.2014070660 [Mendelian randomization in a cohort, n=3,315]
- Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300(8):924-32. PMID: 18728266 · DOI: 10.1001/jama.300.8.924 [RCT, crossover, n=30]
- Gaffo AL, Calhoun DA, Rahn EJ, et al. Effect of Serum Urate Lowering With Allopurinol on Blood Pressure in Young Adults: A Randomized, Controlled, Crossover Trial. Arthritis Rheumatol. 2021;73(8):1514-1522. PMID: 33779064 · DOI: 10.1002/art.41749 [RCT, crossover, n=99]
- Gois PHF, Souza ERM. Pharmacotherapy for hyperuricaemia in hypertensive patients. Cochrane Database Syst Rev. 2020;9(9):CD008652. PMID: 32877573 · DOI: 10.1002/14651858.CD008652.pub4 [Systematic Review, Cochrane, 3 RCTs, n=211]
- Badve SV, Pascoe EM, Tiku A, et al. Effects of Allopurinol on the Progression of Chronic Kidney Disease. N Engl J Med. 2020;382(26):2504-2513. PMID: 32579811 · DOI: 10.1056/NEJMoa1915833 [RCT, n=369, CKD-FIX]
- Doria A, Galecki AT, Spino C, et al. Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. N Engl J Med. 2020;382(26):2493-2503. PMID: 32579810 · DOI: 10.1056/NEJMoa1916624 [RCT, n=530, PERL]
- Kojima S, Matsui K, Hiramitsu S, et al. Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy. Eur Heart J. 2019;40(22):1778-1786. PMID: 30844048 · DOI: 10.1093/eurheartj/ehz119 [RCT, open-label, n=1,070, FREED]
- Sapankaew T, Thadanipon K, Ruenroengbun N, et al. Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials. BMC Nephrol. 2022;23(1):223. PMID: 35739495 · DOI: 10.1186/s12882-022-02850-3 [Meta-analysis, network meta-analysis, 23 RCTs]
- Mackenzie IS, Hawkey CJ, Ford I, et al. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400(10359):1195-1205. PMID: 36216006 · DOI: 10.1016/S0140-6736(22)01657-9 [RCT, open-label, n=5,721]
- White WB, Saag KG, Becker MA, et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018;378(13):1200-1210. PMID: 29527974 · DOI: 10.1056/NEJMoa1710895 [RCT, n=6,190, CARES]
- Mackenzie IS, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020;396(10264):1745-1757. PMID: 33181081 · DOI: 10.1016/S0140-6736(20)32234-0 [RCT, open-label, n=6,128]
- Cipolletta E, Tata LJ, Nakafero G, et al. Association Between Gout Flare and Subsequent Cardiovascular Events Among Patients With Gout. JAMA. 2022;328(5):440-450. PMID: 35916846 · DOI: 10.1001/jama.2022.11390 [Case-control study, n=62,574, plus self-controlled case series, n=1,421]
- Cipolletta E, Zverkova Sandström T, Rozza D, et al. Treat-to-Target Urate-Lowering Treatment and Cardiovascular Outcomes in Patients With Gout. JAMA Intern Med. 2026;186(3):332-342. PMID: 41587055 · DOI: 10.1001/jamainternmed.2025.7453 [Cohort, emulated target trial, n=109,504]
- Stamp LK, Frampton C, Morillon MB, et al. Association between serum urate and flares in people with gout and evidence for surrogate status: a secondary analysis of two randomised controlled trials. Lancet Rheumatol. 2022;4(1):e53-e60. PMID: 38288731 · DOI: 10.1016/S2665-9913(21)00319-2 [RCT, secondary analysis of two trials, n=588]
- Juraschek SP, Gelber AC, Choi HK, et al. Effects of the Dietary Approaches to Stop Hypertension (DASH) Diet and Sodium Intake on Serum Uric Acid. Arthritis Rheumatol. 2016;68(12):3002-3009. PMID: 27523583 · DOI: 10.1002/art.39813 [RCT, secondary analysis of a feeding trial, n=103]
- Choi HK, Willett W, Curhan G. Coffee consumption and risk of incident gout in men: a prospective study. Arthritis Rheum. 2007;56(6):2049-55. PMID: 17530645 · DOI: 10.1002/art.22712 [Cohort, n=45,869]
- Choi HK, Curhan G. Coffee, tea, and caffeine consumption and serum uric acid level: the third national health and nutrition examination survey. Arthritis Rheum. 2007;57(5):816-21. PMID: 17530681 · DOI: 10.1002/art.22762 [Cross-sectional, n=14,758]
- Juraschek SP, Miller ER, Gelber AC. Effect of oral vitamin C supplementation on serum uric acid: a meta-analysis of randomized controlled trials. Arthritis Care Res (Hoboken). 2011;63(9):1295-306. PMID: 21671418 · DOI: 10.1002/acr.20519 [Meta-analysis, 13 RCTs, n=556]
- Stamp LK, O'Donnell JL, Frampton C, et al. Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: a pilot randomized controlled trial. Arthritis Rheum. 2013;65(6):1636-42. PMID: 23681955 · DOI: 10.1002/art.37925 [RCT, pilot study, n=40]
- Zhang Y, Neogi T, Chen C, et al. Cherry consumption and decreased risk of recurrent gout attacks. Arthritis Rheum. 2012;64(12):4004-11. PMID: 23023818 · DOI: 10.1002/art.34677 [Case-crossover, n=633]
- Stamp LK, Chapman P, Frampton C, et al. Lack of effect of tart cherry concentrate dose on serum urate in people with gout. Rheumatology (Oxford). 2020;59(9):2374-2380. PMID: 31891407 · DOI: 10.1093/rheumatology/kez606 [RCT, n=50]
- Dalbeth N, Ames R, Gamble GD, et al. Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomised controlled trial. Ann Rheum Dis. 2012;71(6):929-34. PMID: 22275296 · DOI: 10.1136/annrheumdis-2011-200156 [RCT, proof of concept, n=120]
- Research status: 16 September 2026. S3 guideline in version 2.1, revised 27 August 2024, next review planned for 26 August 2029. For recommendation 7.1, the rationale mentions an upgrade to recommendation grade B, while the recommendation table shows grade 0; the table is cited here. The DEGAM guideline on acute gout from 2023 has been partly superseded by the S3 and is cited only for red flags and laboratory variability; the one on chronic gout expired in 06/2024 and is mentioned for historical reference only.
- The Japanese guideline was not checked in the original. Its position comes from a review whose first author is a co-author of FREED. For EULAR, only the abstract was accessible.
- Conflicts of interest in individual studies. According to the PubMed disclosure for the uricase paper around Kratzer, one co-author is an inventor on patents for lowering uric acid in high blood pressure and kidney disease. CARES was funded by Takeda, FAST by Menarini, Ipsen and Teijin Pharma. This is not a judgment on the results.
- The large diet cohorts come predominantly from US health professionals and show associations, not causes. The analysis around Major describes the population level using cross-sectional data and says nothing about how an individual person responds to a change in diet.
- The mechanisms of fructose in the liver and of ketone bodies in the kidney are textbook physiology without a primary source of their own; the findings on ketone bodies and crystal inflammation come from animal and cell experiments.
- No reliable studies were found on fatigue or water retention as direct uric acid symptoms, on alcohol-free beer, or on apple cider vinegar, baking soda or teas. Test strips, pregnancy, sport and a possible link with cancer were not researched. The figure "roughly 8 mg/dl" for 0.48 mmol/l is an approximation made for this article.
- Figures are taken from the study abstracts. For the papers by FitzGerald 2020, Dalbeth 2021, Li 2017 and Stamp 2022, corrections are listed in PubMed whose content was not checked individually.
- What is deliberately not included here. No doses of colchicine, cortisone, allopurinol or febuxostat, no treatment protocol, no table of normal values and no advice to stop, reduce or replace any medication. Amounts given for vitamin C and aspirin are study data, not recommendations. Nothing in any paragraph implies that a medical assessment or ongoing gout treatment should be postponed or interrupted. The author has no conflicts of interest. The research was AI-assisted and was checked source by source against PubMed and Crossref.